Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease

Bibliography

PubMed

PMID 40274471

PubMed Central

PMC12418413

DOI

10.1016/j.neurot.2025.e00591

Funding

Indexed grant support: R01 NS017950 — NINDS NIH HHS — United States; R01 AG077472 — NIA NIH HHS — United States; TL1 TR002647 — NCATS NIH HHS — United States; P30 AG044271 — NIA NIH HHS — United States; P30 AG072947 — NIA NIH HHS — United States. The indexed list may not contain the complete funding declaration.

Competing interests

Reported disclosure: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ronald C. Petersen reports a relationship with University of Oxford, UpToDate, and Medscape that includes equity or stocks. Ronald C. Petersen reports personal stock in AbbVie. reports personal fees from Roche, Genetech, Eli Lilly, and Nestle, and no personal fees from Eisai, outside of the submitted work. Suzanne Craft reports a relationship with TD3 Therapeutics and Neurodegenerative Consortium that includes board membership. Suzanne Craft reports a relationship with vTv Therapeutics, Cylcerion, T3D Therapeutics, and Cognito Therapeutics, outside the submitted work that includes equity or stock. Randall J. Bateman reports a relationship with C2N Diagnostics and receives income from serving on the scientific advisory board as a co-founder. Randall J. Bateman has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Mitzi M. Gonzales reports personal stock in Abbvie. James L. Kirkland and Tamara Tchkonia are co-investigators on a patent Treating Cognitive Decline and Other Neurodegenerative Conditions by Selectively Removing Senescent Cells from Neurological Tissue and a patent for Treating Cognitive Decline and Other Neurodegenerative Conditions by Selectively Removing Senescent Cells from Neurological Tissue that are held by Mayo Clinic with royalties paid to Mayo Clinic by Unity Biotechnologies. Dallin Mason, Samuel Johnson, and Suzanne Hendrix are employees of Pentara Corporation which provides consulting to over 30 pharmaceutical, biotech, non-profit, and academic groups doing clinical research in neurodegenerative disorders. Suzanne Hendrix is the founder, owner, and CEO of Pentara Corporation. Washington University has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (Stable Isotope Labeling Kinetics, Blood Plasma Assay, and Methods of Diagnosing AD with Phosphorylation Changes) licensed by Washington University to C2N Diagnostics. Miranda Orr has patent Biosignature and Therapeutic Approach for Neuronal Senescence pending. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.